Protara Therapeutics (TARA) awards director 31,000 stock options at $3.94

Rhea-AI Filing Summary

Protara Therapeutics director Gregory Sargen received a grant of stock options covering 31,000 shares of common stock. The options have an exercise price of $3.94 per share, expire on June 14, 2036, and will vest in full on the first anniversary of the June 15, 2026 grant date, or upon a Change of Control, subject to his continued Board service. Following this award, the filing shows 31,000 derivative securities held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SARGEN GREGORY

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 31,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 31,000 options Exercise price: $3.94 per share Underlying shares: 31,000 shares +2 more

5 metrics

Option grant size 31,000 options Stock Option (Right to Buy) awarded June 15, 2026

Exercise price $3.94 per share Conversion or exercise price of stock options

Underlying shares 31,000 shares Common stock underlying the stock options

Post-grant derivative holdings 31,000 options Total derivative securities following transaction

Expiration date June 14, 2036 Option term end date

Key Terms

Stock Option (Right to Buy), Change of Control, Annual Grant

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Change of Control financial

"will vest in full upon a Change of Control"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

Annual Grant financial

"The shares subject to the Annual Grant will vest in full"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/16/2026 - 04:07 PM Accepted by SEC EDGAR 06/16/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SARGEN GREGORY

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.94	06/15/2026		A		31,000		06/15/2027(1)	06/14/2036	Common Stock	31,000	$0	31,000	D

Explanation of Responses:

1. 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

Remarks:

	/s/ Mary Grendell, Attorney-in-fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Protara Therapeutics (TARA) director Gregory Sargen report in this Form 4?

Gregory Sargen reported receiving a grant of stock options for 31,000 shares of Protara common stock. These options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price.

How many Protara Therapeutics (TARA) shares are covered by the new stock options?

The new stock option award covers 31,000 shares of Protara common stock. This represents potential future share ownership if the options are exercised, rather than shares acquired in the market today.

What is the exercise price and term of Gregory Sargen’s Protara stock options?

The options have an exercise price of $3.94 per share and expire on June 14, 2036. This means he can buy up to 31,000 shares at $3.94 any time before that expiration date, once vested.

When do Gregory Sargen’s Protara Therapeutics stock options vest?

The options will vest in full on the first anniversary of the June 15, 2026 grant date, subject to his continued Board service. They will also vest in full upon a Change of Control of Protara, according to the footnote.

Are these Protara (TARA) options an open-market purchase or a compensation grant?

These options are a compensation grant classified as a grant, award, or other acquisition. They were issued at no cost per option, giving Sargen the right to buy shares at $3.94 rather than reflecting cash buying in the market.